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ABSTRACT
Objective Prognostic stratification of patients with
cirrhosis is common clinical practice. This study compares
the prognostic accuracy (28-day and 90-day transplant-
free mortality) of the acute-on-chronic liver failure (ACLF)
classification (no ACLF, ACLF grades 1, 2 and 3) with
that of acute kidney injury (AKI) classification (no AKI,
AKI stages 1, 2 and 3).
Design The study was performed in 510 patients with
an acute decompensation of cirrhosis previously included
in the European Association for the Study of the Liver–
Chronic Liver Failure consortium CANONIC study. ACLF
was evaluated at enrolment and 48 h after enrolment,
and AKI was evaluated at 48 h according to Acute
Kidney Injury Network criteria.
Results 240 patients (47.1%) met the criteria of ACLF
at enrolment, while 98 patients (19.2%) developed AKI.
The presence of ACLF and AKI was strongly associated
with mortality. 28-day transplant-free mortality and 90-
day transplant-free mortality of patients with ACLF (32%
and 49.8%, respectively) were significantly higher with
respect to those of patients without ACLF (6.2% and
16.4%, respectively; both p<0.001). Corresponding
values in patients with and without AKI were 46% and
59%, and 12% and 25.6%, respectively (p<0.0001 for
both). ACLF classification was more accurate than AKI
classification in predicting 90-day mortality (area under
the receiving operating characteristic curve=0.72 vs 0.62;
p<0.0001) in the whole series of patients. Moreover,
assessment of ACLF classification at 48 h had significantly
better prognostic accuracy compared with that of both
AKI classification and ACLF classification at enrolment.
Conclusions ACLF stratification is more accurate than
AKI stratification in the prediction of short-term mortality
in patients with acute decompensation of cirrhosis.
INTRODUCTION
The assessment of patients at risk of poor outcome
is a crucial point in clinical practice since it helps
the physician to decide on the intensity of treat-
ment and monitoring and the most appropriate
setting for patients’ management (intensive care
unit or regular ward). For this reason, interest in
assessing organ dysfunction and severity of illness
in hospitalised patients with cirrhosis has increased
in recent years. This interest has grown in parallel
with the development of the concept of
acute-on-chronic liver failure (ACLF) that, in its
Significance of this study
What is already known on this subject?
▸ Acute kidney injury (AKI) is a frequent
complication of cirrhosis and a powerful
predictor of death in hospitalised patients with
liver cirrhosis.
▸ Acute-on-chronic liver failure (ACLF) is a clinical
syndrome characterised by an acute
deterioration of liver function and the
development of organ failure in patients with
chronic liver disease.
▸ The Chronic Liver Failure–Sequential Organ
Failure Assessment (CLIF–SOFA) score has been
shown to be a powerful predictor of death in
hospitalised patients with cirrhosis.
What are the new findings?
▸ The development of ACLF according to CLIF–
SOFA score was found to be more accurate
than AKI classification in the prediction of
short-term mortality in patients with cirrhosis
who are hospitalised for an acute
decompensation of the liver disease.
▸ The assessment of CLIF–SOFA score after 48 h
further improved the prognostic accuracy of
ACLF classification.
▸ ACLF classification is able to predict the
prognosis of patients with cirrhosis in a
stage-dependent fashion, stratifying the
mortality risk.
How might it impact on clinical practice in
the foreseeable future?
▸ The ACLF classification is a simple tool able to
identify patients with cirrhosis with high risk of
short-term mortality.
▸ The ACLF classification may be able to identify
high-risk patients requiring an intensive care
management.
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simplest terms, is characterised by the abrupt onset of organ fail-
ures in patients with cirrhosis hospitalised for an acute decom-
pensation of liver disease.1 The CLIF Acute-on-chronic liver
failure in cirrhosis (CANONIC) study demonstrated that the
presence of two (ACLF grade 2) or three organ failures (ACLF
grade 3), which were defined by a Sequential Organ Failure
Assessment (SOFA) score specifically adapted to patients with
cirrhosis (CLIF-SOFA score) is associated with a high short-term
mortality rate.1
In single-organ failure (ACLF grade 1), an increased mortality
rate was observed for patients with kidney failure defined by a
serum creatinine (sCr) >2 mg/dL or with a failure of an organ
other than the kidney when it is associated with an sCr
>1.5 mg/dL or with grade 1 or 2 hepatic encephalopathy.1 For
many years, a cut-off level of 1.5 mg/dL of sCr has been used
for the diagnosis of impairment of kidney function in patients
with cirrhosis even when an increase of sCr with respect to
baseline was considered.2–5 Consequently, the results of the
CANONIC study have reinforced the concept that an impair-
ment of kidney function has a marked negative impact on prog-
nosis of hospitalised patients with cirrhosis, giving it a new
dimension as a predictor of mortality.
In 2007, the Acute Kidney Injury Network (AKIN) devel-
oped a consensus definition of AKI, a new term to define acute
renal failure according to AKIN criteria.6 The main innovative
aspects introduced by AKIN criteria are the following: (a) an
absolute increase in sCr is considered without any final cut-off
value and (b) a staging system of AKI based on changes of sCr
within 48 h. These criteria are being used extensively in critic-
ally ill patients since they have been shown to be accurate in
predicting prognosis.7 However, the information about AKIN
criteria for diagnosis and classification of AKI in patients with
cirrhosis is still limited. Recently, four prospective studies have
shown that the AKI classification based on AKIN criteria pre-
dicts short-term and mid-term mortality in a stage-dependent
fashion in hospitalised patients with cirrhosis.8–11 The results
indicate that the AKI classification is useful in the prognostic
stratification of patients with cirrhosis. Nevertheless, the AKI
classification has so far not been compared with a more com-
plete assessment of organ failures in these patients. Thus, the
current study was designed to compare prospectively the AKI
classification and the classification of ACLF in the prognostic




The current study was performed in a population of patients
included in the CANONIC study.1 The CANONIC study was a
multicentre study aimed at evaluating the frequency, character-
istics and outcome of ACLF in patients with cirrhosis admitted
for an acute decompensation of the disease in 29 liver units from
8 European countries. Patients included in the current investiga-
tion were patients belonging to groups 1 and 2 of the CANONIC
study. The distribution of patients in the CANONIC study has
been reported in detail elsewhere.1 Briefly, patients in group 1
were patients admitted to hospital for an acute decompensation
of cirrhosis who had at least one organ failure at admission to
hospital, while patients in group 2 were patients admitted for an
acute decompensation of cirrhosis but without organ failure that
were chronologically enrolled after each patient with organ
failure. In patients from both groups, clinical and laboratory data
were collected at enrolment, 2 days after enrolment and at differ-
ent time intervals throughout the hospitalisation, specifically
3–7, 8–14, 15–21 and 22–28 days after enrolment. Patients from
group 3 of the CANONIC study were not included in the current
investigation because laboratory data were collected at the time
of enrolment but not throughout hospitalisation. A total of 639
patients from groups 1 and 2 were evaluated for inclusion in the
current study. Of these patients, 129 were excluded because of at
least one of the following reasons: lack of sCr values at day 2 (68
cases), lack of one or more variables included in the ACLF defin-
ition at day 2 (51 patients) and death or liver transplantation one
day after enrolment (12 patients). Therefore, the current study
was carried out in 510 patients. The distribution of patients is
shown in online supplementary figure S1.
Main variables and definitions
The study was aimed at evaluating the AKI classification as well
as the ACLF classification1 12 in determining the outcome of
patients hospitalised for an acute decompensation of cirrhosis.
AKI was defined using the new Kidney Disease Improving
Global Outcomes AKIN criteria and patients were categorised
into 4 groups: no AKI and AKI stages 1, 2 and 3 (see online
supplementary table S1).12 According to this classification, a
patient was considered to developing AKI when there was an
increase in sCr ≥0.3 mg/dL or ≥50% in two different measure-
ments obtained 48 h apart. The baseline sCr used was that
obtained at enrolment of patients in the study while the second
measurement was collected 2 days after enrolment.
ACLF was defined according to the presence and severity of
organ failures as described in the CANONIC study, and patients
were classified into 4 different groups: (1) no ACLF, (2) ACLF
grade 1, (3) ACLF grade 2 and (4) ACLF grade 3 (see online
supplementary table S1).1 Outcome was analysed as 28-day and
90-day mortality.
Statistical analysis
Data were collected using an electronic case report form.
Quantitative variables are reported as mean and SD or median,
minimum and maximum according to their nature. Categorical
variables are reported as count and percentage in each category
and total. Factors associated with the development of AKI,
ACLF and mortality were identified in a bivariate analysis with
Student t test and one-way analysis of variance for quantitative
variables (depending on the number of categories), or the non-
parametric corresponding tests, if needed. The 28-day and
90-day mortality rates were estimated as transplant-free mortal-
ity. In addition, since transplantation can be considered a com-
peting event of death, curves showing the cumulative
probability of failure were estimated with the cumulative inci-
dence function proposed by Fine and Gray13 due to the lack of
validity of the Kaplan–Meier estimator in this context.
The accuracy of AKI and ACLF classifications in predicting
28-day and 90-day transplantation-free mortality was assessed
estimating the area under the curve of the receiving operating
characteristic (AUCROC). Furthermore, they were compared in
order to establish the better classification in prognosis. In a
similar way, classification’s accuracy for the estimation of both
mortalities under a competing risk approach was assessed with
the C-index and compared with the integrated discrimination
improvement index. Two-sided p values of <0.05 were consid-
ered to indicate statistical significance.
RESULTS
Baseline characteristics of the patients
The demographic, clinical and laboratory characteristics of
patients at the time of enrolment in the study are shown in table 1.
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The majority of patients had advanced cirrhosis as indicated by
markedly impaired liver function tests and high Child–Pugh and
model for end-stage liver disease (MELD) scores.
Frequency and characteristics of AKI and relationship with
outcome
In total, 98 of the 510 patients (19.2%) developed AKI during
the first 48 h after enrolment. In these patients, sCr concentra-
tion increased from 2.5±1.9 at baseline to 2.7±1.9 mg/dL at
day 2 (p=0.0064). Corresponding values of sCr in the 412
patients who did not develop AKI were 1.4±1.1 and 1.2
±0.9 mg/dL, respectively (p<0.0001). In total, 34 of 98
patients (34.7%) who developed AKI had AKI stage 1, 4 (4.1%)
stage 2 and 60 (61.2%) stage 3. The relatively high proportion
of patients with AKI stage 3 was largely due to the need for
renal replacement therapy in 50 of 60 patients (83.3%) who
had AKI stage 3. Values of sCr according to the different AKI
stages are shown in online supplementary figure S2.
Table 2 shows the comparison of baseline characteristics of
patients categorised according to the subsequent development
of AKI within the 48 h time frame. Patients who developed AKI
had more frequent history of arterial hypertension, higher fre-
quency of ascites and hepatic encephalopathy, and lower mean
arterial pressure and higher heart rate compared with patients
who did not develop AKI. Moreover, patients who developed
AKI had more severe impairment of liver function, higher sCr
levels and higher leucocyte count and C-reactive protein levels
compared with those of patients who did not develop AKI. The
frequency of ascites and encephalopathy and the magnitude of
changes in laboratory tests paralleled the presence and severity
of AKI (see online supplementary table S2).
The development of AKI was associated with precipitating
factors in most patients, particularly bacterial infections and
volume depletion. In addition, 15 of 98 patients had type 1
hepatorenal syndrome, according to the International Ascites
Club14 15 (table 3).
The presence of AKI at 48 h after enrolment had a strong
association with prognosis in a stage-dependent manner.
Twenty-eight-day transplant-free mortality in patients with AKI
Table 1 Baseline characteristics of patients at enrolment (n=510)
Age (years) 55±12 (22–95)
Male sex 331 (65)
Aetiology of cirrhosis
Alcohol 292 (60)
Hepatitis C virus 67 (13)
Alcohol plus hepatitis C virus 46 (9)




GI bleeding 114 (24)
Spontaneous bacterial peritonitis 50 (11)
Concomitant diseases
Arterial hypertension 104 (21)
Diabetes mellitus 108 (22)




Bacterial infection 124 (25)
GI bleeding 79 (16)
Other 177 (35)
Exploratory data
Mean arterial pressure (mm Hg) 82±12 (46–122)
Heart rate (bpm) 83±17 (45–150)
Laboratory data
White blood cells (×109/L) 9±5 (0.8–50)
Platelet count (×109/L) 102±7 (12–543)
Serum bilirubin (mg/dL) 8±9 (0.5–45.5)
Serum albumin (g/dL) 2.8±0.5 (1.3–4.5)
International normalised ratio 1.9±0.7 (1–7)
Plasma C-reactive protein (mg/L) 38±42 (0.6–326)
Serum creatinine (mg/dL) 1.6±1.3 (0.4–12.5)
Serum sodium (mmol/L) 134±6 (111–153)
Child-Pugh score 10±2 (5–15)
MELD 22±8 (6–40)
Data are expressed as mean±SD (min-max) or number of patients (percentage).
MELD, model for end-stage liver disease.
Table 2 Baseline characteristics of patients at enrolment
according to the subsequent development of acute kidney injury
(AKI) at 48 h after enrolment
No AKI (n=412) AKI (n=98) p Value
Age (years) 56±11 53±14 0.09
Male sex 270 (65) 61 (62) 0.53
Aetiology of cirrhosis
Alcohol 243 (61) 49 (52) 0.07
Hepatitis C virus 56 (14) 11 (12) 0.50
Alcohol plus hepatitis C virus 37 (9) 9 (9) 0.98
Other causes 58 (15) 26 (27) 0.003
Previous decompensation(s)
Ascites 250 (65) 60 (63) 0.79
Encephalopathy 126 (33) 26 (28) 0.36
GI bleeding 98 (26) 16 (17) 0.09
Spontaneous bacterial peritonitis 41 (11) 9 (10) 0.74
Concomitant diseases
Arterial hypertension 76 (19) 28 (29) 0.03
Diabetes mellitus 83 (20) 25 (25) 0.28
Chronic renal failure 36 (9) 9 (9) 0.93
Cause(s) of admission
Ascites 274 (68) 77 (79) 0.02
Encephalopathy 142 (35) 48 (49) 0.01
Bacterial infection 95 (24) 29 (30) 0.23
GI bleeding 68 (17) 11 (11) 0.18
Other 147 (36) 30 (31) 0.27
Exploratory data
Mean arterial pressure (mm Hg) 82±12 79±12 0.007
Heart rate (beats/min) 83±17 87±19 0.02
Laboratory data
White blood cells (×109/L) 8.2±5.3 10.4±7.2 0.0005
Platelet count (×109/L) 103±72 99±65 0.84
Serum bilirubin (mg/dL) 7±8.2 12±12 0.0004
Serum albumin (g/dL) 2.8±0.6 2.7±0.6 0.26
International normalised ratio 1.8±1 2.2±1 <0.0001
Plasma C-reactive protein (mg/L) 35±39 52±50 0.0003
Serum creatinine (mg/dL) 1.4±1.1 2.5±2 <0.0001
Serum sodium (mmol/L) 135±6 133±6 0.06
Child–Pugh score 10±2 11±2 <0.0001
MELD 21±7 28±87 <0.0001
Data are expressed as mean±SD or number of patients (percentage).
MELD, model for end-stage liver disease.
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stage 2–3 was 55.9% compared with 25% in patients with AKI
stage 1 and 12% in patients without AKI (p<0.0001).
Corresponding values of 90-day transplant-free mortality were
67.3%, 40% and 25.6%, respectively (p<0.0001). During the
90-day period after enrolment, 63 patients (12.5%) were trans-
planted, 17 with AKI and 46 without AKI (17.5% and 11.4%
from the AKI and non-AKI groups, respectively; p=0.09).
Because transplantation can be considered a competing event
of death, the cumulative incidence function of mortality during
follow-up was assessed using a competing risk approach (see the
Methods section). As shown in figure 1, presence and severity
of AKI was clearly associated with 28-day and 90-day cumula-
tive mortality risk.
ACLF at enrolment and relationship with outcome
In total, 240 of 510 patients (47.1%) met the criteria of ACLF
at enrolment in the study: 110 had ACLF grade 1 (45.8%), 96
grade 2 (40%) and 34 (14.2%) grade 3. The comparison of the
baseline characteristics of patients with and without ACLF is
shown in table 4. Patients with ACLF at enrolment had higher
frequency of ascites and hepatic encephalopathy at admission
and lower frequency of GI bleeding compared with patients
without ACLF. Surprisingly, there were no significant differences
between the two groups with respect to the frequency of bacter-
ial infections. Patients with ACLF had more frequent history of
arterial hypertension and chronic kidney disease, and more
severe impairment of liver function tests, higher sCr, lower
serum sodium and arterial pressure, and higher white blood cell
count and plasma C-reactive protein levels at enrolment with
respect to patients without ACLF (table 4). The frequency of
Table 3 Potential causes of acute kidney injury




Bacterial infection 47 (39)
Spontaneous bacterial peritonitis 17
Pneumonia 9
Urinary tract infection 7
Skin infection 4
Other infections 4
Unproved suspected infection 6
Type 1 hepatorenal syndrome 15 (12)
Surgery 2 (2)
Unknown 37 (30)
Values are number of patients and percentages (in parentheses).
Patients could have more than one potential cause: 41 patients had one, 19 had two
and 1 had three. The cause was unknown in 37 patients.
Figure 1 Probability of survival of all
patients included, categorised
according to the presence and severity
of acute kidney injury (AKI) 48 h after
enrolment. Calculations were
performed using competing risks
approach (see text). (A) 28-day
survival; (B) 90-day survival.
Table 4 Baseline characteristics of patients according to the





Age (years) 55±12 55±11 0.46
Male sex 173 (64) 158 (34) 0.68
Aetiology of cirrhosis
Alcohol 151 (58) 141 (61) 0.49
Hepatitis C virus 39 (15) 28 (12) 0.35
Alcohol plus hepatitis C virus 24 (9) 22 (0.4) 0.91
Other causes 45 (17) 39 (17) 0.90
Previous decompensation(s)
Ascites 161 (63) 149 (66) 0.49
Encephalopathy 79 (31) 73 (33) 0.62
GI bleeding 62 (24) 52 (24) 0.81
Spontaneous bacterial peritonitis 26 (10) 24 (11) 0.83
Concomitant diseases
Arterial hypertension 46 (17) 58 (24) 0.04
Diabetes mellitus 54 (20) 54 (23) 0.48
Chronic renal failure 14 (5) 31 (13) 0.002
Cause(s) of admission
Ascites 170 (64) 181 (76) 0.003
Encephalopathy 81 (30) 109 (46) 0.0003
Bacterial infection 59 (23) 65 (29) 0.13
GI bleeding 51 (19) 28 (12) 0.02
Other 94 (35) 83 (35) 0.99
Exploratory data
Mean arterial pressure (mm Hg) 84±11 79±13 <0.0001
Heart rate (beats/min) 84±16 83±18 0.63
Laboratory data
White blood cells (×109/L) 7.3±4.4 10.1±6.7 <0.0001
Platelet count (×109/L) 104±70 101±73 0.35
Serum bilirubin (mg/dL) 5.6±6.3 11±11 <0.0001
Serum albumin (g/dL) 2.7±0.6 2.8±0.6 0.14
International normalised ratio 1.7±0.6 2.1±0.9 <0.0001
Plasma C-reactive protein (mg/L) 33±39 45±0.6 0.0009
Serum creatinine (mg/dL) 1.0±0.4 2.4±1.6 <0.0001
Serum sodium (mmol/L) 135±6 134±6 0.004
Child–Pugh score 10±2 11±2 <0.0001
MELD 18±6 27±7 <0.0001
Data are expressed as mean±SD or number of patients (percentage).
MELD, model for end-stage liver disease.
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ascites and encephalopathy and the magnitude of changes in
laboratory tests changed in parallel with severity of ACLF (see
online supplementary table S3).
The frequency and stages of ACLF in patients categorised
according to the absence or presence of AKI and its stage are
shown in online supplementary figure S3.
The presence of ACLF at enrolment was strongly associated
with mortality. Twenty-eight-day transplant-free mortality in
patients with ACLF was 32% compared with only 6.2% in
patients without ACLF (p<0.0001). Corresponding values of
90-day transplant-free mortality were 49.8% and 16.4%, respect-
ively (p<0.001). During the 3-month period after enrolment, 35
(14.6%) patients with ACLF and 28 (10.4%) patients without
ACLF were transplanted (p=0.15). In a way similar to the ana-
lysis performed with AKI, the cumulative incidence function of
mortality during follow-up of all patients categorised according
to the presence and severity of ACLF was assessed using risk esti-
mates adjusted to the competing risk of transplantation. As
shown in figure 2, presence and severity of ACLF was clearly
associated with 28-day and 90-day cumulative mortality risk.
Comparison of the prognostic value of AKI classification vs
ACLF classification
We then compared the accuracy of the two classifications in pre-
dicting 28-day and 90-day mortality in the whole series of
patients admitted to hospital for management of an acute
decompensation of cirrhosis. The AUCROC for predicting
transplant-free mortality was significantly better for the ACLF
classification compared with that of the AKI classification, both
at 28 and 90 days (table 5). Likewise, the comparison of the
two classifications under a competing risk analysis approach was
also better for ACLF compared with AKI.
We then analysed whether assessment of presence and severity
of ACLF after 2 days of enrolment (that is, at the same day that
the AKI classification was assessed) had better prognostic accur-
acy than assessment of ACLF at enrolment. During the 2-day
period after enrolment, 28 of 270 patients (10.4%) who did not
have ACLF at baseline developed ACLF (grade 1 in 16 patients,
grade 2 in 11 patients and grade 3 in 1 patient). By contrast, 64
of 240 patients (26.7%) who had ACLF at enrolment improved
and no longer met the criteria of ACLF at day 2 (previous
ACLF grades were 1 in 43 patients, 2 in 18 patients and 3 in 3
patients). Assessment of ACLF classification at day 2 had signifi-
cantly better prognostic accuracy compared with those of AKI
classification and ACLF classification at enrolment, both using
comparisons of standard AUCROC curves for transplant-free
mortality as well as comparisons under a competing risk
approach considering transplant as a competing event of death
(table 5). The predictive accuracy of the model was similar
according to the different aetiologies of cirrhosis (alcoholic cir-
rhosis vs hepatitis C or B infection).
Causes of death and effect of bacterial infections
Table 6 shows the causes of death during the 28-day period in
patients classified according to the presence or absence of ACLF
at 48 h after enrolment. As expected, mortality was markedly
higher in patients with ACLF than in those without
(p<0.0001). There were no significant differences between the
two groups with respect to causes of death.
Among the 510 patients included, 150 developed a bacterial
infection (29.4%). The prevalence of infection increased with
the presence and severity of ACLF. More importantly, mortality
in patients with infections correlated also with presence and
severity of ACLF (table 7).
Figure 2 Probability of survival of all
patients included, categorised
according to the presence and severity
of acute-on-chronic-liver-failure (ACLF)
at enrolment. Calculations were
performed using competing risks
approach (see text). (A) 28-day
survival; (B) 90-day survival.
Table 5 Comparison of acute kidney injury (AKI) and acute-on-chronic liver failure (ACLF) classifications to predict 28-day and 90-day mortality
AKI ACLF at enrolment ACLF at 48 h
AKI vs ACLF
at enrolment AKI vs ACLF at 48 h
ACLF at enrolment
vs ACLF at 48 h
AUCROC* p Value
28-day 0.68 (0.62 to 0.73) 0.77 (0.71 to 0.82) 0.84 (0.80 to 0.89) 0.0049 <0.0001 0.0021
90-day 0.62 (0.57 to 0.66) 0.72 (0.67 to 0.77) 0.77 (0.73 to 0.82) <0.0001 <0.0001 0.0092
C-index† p Value
28-day 0.66 (0.61 to 0.71) 0.74 (0.69 to 0.79) 0.81 (0.76 to 0.85) 0.09 <0.0001 0.0004
90-day 0.61 (0.57 to 0.65) 0.69 (0.65 to 0.73) 0.74 (0.70 to 0.77) 0.0028 <0.0001 0.0002
Values in parentheses are 95% CIs.
*Transplant-free mortality.
†Mortality considering transplantation as competing event.
AUCROC, area under the curve of the receiving operating characteristic.
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DISCUSSION
The purpose of the current study was to compare the accuracy of
the AKI classification with that of the ACLF classification, recently
proposed by the European Association for the Study of the Liver
(EASL)–CLIF consortium on the basis of the CANONIC study, in
the prediction of 28-day and 90-day mortality in patients hospita-
lised for an acute decompensation of cirrhosis.1
The main result of the study is that the ACLF classification has
greater prognostic accuracy compared with that of the AKI classi-
fication in the prediction of 28-day and 90-day mortality. This
holds true considering the ACLF classification at enrolment, but
more especially when patients were stratified according to the
ACLF classification at 48 h of enrolment. This greater prognostic
accuracy of the ACLF system is first of all due to the fact that, in
contrast to the AKIN criteria, it includes in its definition also
non-kidney organ failures such as encephalopathy and cardiovas-
cular dysfunction that are known to have a strong negative
impact on prognosis of patients with cirrhosis. In addition, the
diagnosis of ACLF also includes liver and coagulation failures,
based on the use of serum bilirubin and international normalised
ratio, respectively, that are known to have a strong predictive
value on 90-day mortality in these patients.16–18 The availability
of a classification system, like the current one on ACLF, which is
simple in its application and also able to provide an accurate
prognostic assessment at the point of enrolment, is a key factor
for planning the management of a severe clinical condition like
acute decompensation of cirrhosis. In particular, the identifica-
tion of patients with a high risk of mortality would be invaluable
in deciding when and in which patients to intensify medical care,
and in selecting those for liver transplantation. Recognition of
high-risk patients with an acute decompensation of the liver
disease could facilitate focused resource allocation by identifying
those most likely to benefit. Finally, subsequent research in this
field can help stratify diagnostic and therapeutic findings between
high-risk and low-risk subsets of patients, thereby promoting a
targeted evaluation and/or application of them.
Approximately 20% of the population of the current study
developed AKI within the first 48 h after enrolment. The design
of the CANONIC study may have favoured an underestimation
of the actual prevalence of AKI in our series of patients. In fact,
according to the definition of the AKIN criteria, only changes in
sCr within the first 48 h after enrolment were considered for
the definition of AKI. Therefore, patients who could theoretic-
ally have developed AKI before or after this interval of time
were not considered. Looking at the baseline sCr in patients
without AKI (see online supplementary figure S2) it is possible
that some patients could have developed AKI before enrolment
and probably before admission to hospital. It has been reported
that a community-acquired AKI may account for at least
one-third of all AKI episodes detected in general population.19
However, the detection of community-acquired AKI criteria
requires an sCr value to be evaluated just prior to hospital
admission or a surrogate for it. Thus, the lack of this value
represents more a limitation of applicability of the AKIN criteria
than of the study design. As far as the possibility of development
of AKI later during the hospitalisation, it should be taken into
account that it has been observed that most AKI episodes occur
during the first 48 h after admission.20 On the other hand, the
possibility that some patients could have developed ACLF more
than 48 h after enrolment should also be taken into account.
Thus, the comparison limited to the first 48 h, that is, at the
same day that the AKI classification was assessed, puts the two
classification systems in a condition of virtual equality. Despite
this equality, the ACLF classification made it possible to stratify
in prognostic terms 47.1% of patients at enrolment and 40% of
patients after 48 h. A number of factors could have contributed
to this high frequency of ACLF. First, among patients who had
an organ failure at enrolment those with an organ failure other
than the kidney were 41.7%. Second, the use of an absolute
value of sCr ≥1.5 mg/dL, which has always shown a high prog-
nostic value in hospitalised patients with cirrhosis, without suf-
fering the methodological limitations of the AKIN criteria, has
contributed to define an additional 10.4% of patients with
ACLF. Finally, to fully understand the significance of this
marked difference in frequency between AKI and ACLF in our
patients, it is necessary to add that among the patients in whom
AKI was diagnosed only 15.3% did not have ACLF (see online
supplementary figure S3).
One downside of the study appeared when trying to analyse
the prognostic accuracy of the model based on ACLF classifica-
tion for prediction of adverse events. Unfortunately, this analysis
could not be done because the number of patients without
adverse events in the current series of patients was very low
(only 10% of the series), which precluded a conclusive statistical
analysis. Moreover, when adverse events related to organ fail-
ures were considered, there was a problem that organ failures
were included in the definition of ACLF, which made the ana-
lysis not possible.
A final aspect of the study that should be emphasised is that
the prognostic stratification of patients was done in the first
48 h after admission. However, this is an important period of
time in which clinical decisions must be taken.
In conclusion, the ACLF classification provides a simple tool
for an immediate stratification of patients with acute decompen-
sation of cirrhosis on hospital admission. The prognostic accur-
acy of ACLF classification can be further enhanced when it is
Table 6 Causes of death in the whole series categorised
according to the presence or absence of acute-on-chronic liver
failure (ACLF) at 48 h after enrolment
Cause No ACLF (n=306) ACLF (n=204)
Septic shock 3 (25) 32 (42)
Multiorgan failure 3 (25) 22 (29)
Hypovolemic shock 2 (17) 12 (16)
Other 0 (0) 7 (9)
Unknown 4 (33) 3 (4)
Total 12 (4) 76 (37)
Data are expressed as number of patients (values in parentheses are percentages).
Percentages in ‘Total’ refer to the number of patients in each group (no ACLF and
ACLF). In the other rows percentages refer to the number of deaths in each group (no
ACLF vc ACLF).
Table 7 Prevalence and mortality of bacterial infections in













Bacterial infection 82 (27) 30 (33) 16 (25) 22 (49) 0.017
Death
28-day 3 (4) 7 (23) 7 (44) 15 (68) <0.0001
90-day 14 (17) 10 (35) 9 (56) 17 (77) <0.0001
Data are expressed as number of patients (values in parentheses are percentages).
Hepatology
Angeli P, et al. Gut 2015;64:1616–1622. doi:10.1136/gutjnl-2014-307526 1621
group.bmj.com on April 28, 2017 - Published by http://gut.bmj.com/Downloaded from 
applied 48 h after admission. The ACLF classification both at
admission and at 48 h has better prognostic accuracy than the
AKI classification, thus it should be used in the prognostic strati-
fication of these patients.
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